SVRA Savara Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1160308 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-32.1%
TTM EPS YoY-13.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-151.0%
ROA-102.9%
ROIC (approx.)-114.7%
Asset turnover—
Leverage & solvency
Liabilities / assets30.8%
Debt / equity0.28x
Current ratio8.55x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-15.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $81.40M | $78.03M | $44.26M | $27.88M | $28.99M |
| SG&A expense | $42.06M | $25.04M | $15.67M | $10.93M | $12.35M |
| Operating income | -$123.55M | -$103.20M | -$60.01M | -$38.84M | -$41.48M |
| Pretax income | -$118.84M | -$95.88M | -$54.70M | -$38.15M | -$43.01M |
| Income tax | $0 | $9,000 | — | — | — |
| Net income | -$118.84M | -$95.88M | -$54.70M | -$38.15M | -$43.01M |
| EBITDA | -$123.46M | -$103.07M | -$59.93M | -$38.81M | -$41.34M |
| EPS (basic) | -0.53 | -0.48 | -0.33 | -0.25 | -0.32 |
| EPS (diluted) | -0.53 | -0.48 | -0.33 | -0.25 | -0.32 |
| Weighted avg. shares (diluted) | 222.39M | 198.19M | 165.20M | 152.77M | 133.92M |
| Balance sheet | |||||
| Cash & equivalents | $33.18M | $15.13M | $26.59M | $52.10M | $34.01M |
| Short-term investments | $202.52M | $181.20M | $135.73M | $73.78M | $127.16M |
| Current assets | $241.62M | $202.13M | $165.95M | $128.95M | $165.00M |
| PP&E, net | $100,000 | $165,000 | $270,000 | $51,000 | $73,000 |
| Total assets | $253.44M | $212.88M | $177.56M | $139.78M | $176.60M |
| Current liabilities | $20.40M | $14.72M | $10.60M | $5.87M | $14.66M |
| Short-term debt | $0 | $0 | — | — | $8.33M |
| Long-term debt | $29.91M | $26.62M | $26.35M | $26.08M | $17.32M |
| Total debt | $29.91M | $26.62M | $26.35M | $26.08M | $25.66M |
| Total liabilities | $50.30M | $41.43M | $37.19M | $32.00M | $32.10M |
| Shareholders' equity | $203.13M | $171.45M | $140.37M | $107.78M | $144.50M |
| Net debt | -$3.27M | $11.49M | -$237,000 | -$26.02M | -$8.36M |
| Shares outstanding | 204.57M | 172.42M | 138.14M | 114.05M | 114.04M |
| Cash flow statement | |||||
| Operating cash flow | -$101.04M | -$89.09M | -$51.06M | -$34.55M | -$40.08M |
| Capital expenditure | $22,000 | $25,000 | $296,000 | $9,000 | $57,000 |
| Free cash flow | -$101.06M | -$89.11M | -$51.36M | -$34.56M | -$40.14M |
| Investing cash flow | -$18.44M | -$39.94M | -$57.12M | $52.65M | -$69.46M |
| Financing cash flow | $137.81M | $117.58M | $82.78M | $87,000 | $120.81M |
| Depreciation & amortization | $87,000 | $130,000 | $77,000 | $31,000 | $136,000 |
| Stock-based compensation | $14.42M | $9.86M | $4.18M | $2.04M | $3.26M |
Free plan shows the latest 5 periods; Pro shows all 29 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.